AnaCardio

Biotechnology Research • Stockholm, Stockholm County, Sweden • 21-50 Employees

Company overview

Headquarters	Nanna Svartz väg 4, Innomedicum, Solna, Stockholm County 171 65, SE
Website	anacardio.com
NAICS	541714
Employees	21-50
Socials

Key Contacts at AnaCardio

Jørgen Søberg Petersen

Non Executive Director, Board Of Directors

Michael Grissinger

Chair Of The Board Of Directors

AnaCardio Email Formats

AnaCardio uses 2 email formats. The most common is {first name}.{last name} (e.g., john.doe@anacardio.com), used 63.6% of the time.

Format	Example	Percentage
{first name}.{last name}	john.doe@anacardio.com	63.6%
{first initial}.{last name}	j.doe@anacardio.com	36.4%

About AnaCardio

AnaCardio AB is a privately held clinical stage biopharmaceutical company developing novel drugs to treat heart failure. AnaCardio was founded based on ground-breaking research from Karolinska Institutet showing improved contractility of the heart muscle through a unique and differentiated mechanism. The Company’s lead program AC01, a first-in-class calcium sensitizing inotrope, is an oral ghrelin mimetic small-molecule, which was in-licensed from Helsinn and is now being developed as a contractile agent in heart failure patients. The company has raised over USD 40 million to date. AnaCardio is based in Stockholm, Sweden. You can find more information about AnaCardio at www.anacardio.com.

AnaCardio revenue & valuation

Annual revenue	$2,000,000
Revenue per employee	$80,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$6,400,000
Total funding	$32,400,000